GOVX Share Price Performance
US$0.68
-18.72 (-96.49%)
95.1% undervalued intrinsic discount
US$14.00
Fair Value
Price US$0.68
AnalystHighTarget US$14.00
AnalystConsensusTarget US$10.00
AnalystLowTarget US$6.00
Fair ValueUS$14.00
Share Pricen/a
GeoVax Labs, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 28 Fair Values set on narratives written by author
GOVX Community Narratives
AN
Fair Value
·Fair Value US$14 95.1% undervalued intrinsic discount
Diversified Vaccine And Cancer Therapy Platform Will Transform Long Term Earnings Potential
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value US$10 93.2% undervalued intrinsic discount
Regulatory Advances And Pipeline Expansion Will Unlock Future Potential
0users have liked this narrative
0users have commented on this narrative
20users have followed this narrative
AN
Fair Value
·Fair Value US$6 88.6% undervalued intrinsic discount
Mpox And Smallpox Trial And Funding Setbacks Will Eventually Support A Stronger Outlook
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Regulatory Advances And Pipeline Expansion Will Unlock Future Potential
GeoVax Labs says new regulatory guidance and growing interest from governments could help its mpox and smallpox vaccine reach the market sooner than expected. But big cash needs, lost government support, and long clinical timelines mean the upside hinges on winning new partners and hitting key trial milestones.Read more
AN
US$10
93.2% undervalued intrinsic discount
Fair Value
Profit Margin
18.92%
Future PE
9.42x
Price in 2029
US$6.48
Mpox And Smallpox Trial And Funding Setbacks Will Eventually Support A Stronger Outlook
Catalysts About GeoVax Labs GeoVax Labs develops vaccines and cancer therapies focused on unmet medical needs in infectious disease and oncology. What are the underlying business or industry changes driving this perspective?Read more
AN
US$6
88.6% undervalued intrinsic discount
Fair Value
Profit Margin
12.19%
Future PE
5.3x
Price in 2029
US$4.1
Diversified Vaccine And Cancer Therapy Platform Will Transform Long Term Earnings Potential
Catalysts About GeoVax Labs GeoVax Labs develops novel cancer therapies and infectious disease vaccines targeting high unmet medical needs worldwide. What are the underlying business or industry changes driving this perspective?Read more
AN
US$14
95.1% undervalued intrinsic discount
Fair Value
Profit Margin
73.47%
Future PE
1.05x
Price in 2028
US$9.57
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
GOVX: Mpox And Ebola Vaccine Refocus Will Drive Future Upside
Fair Value: US$10 93.2% undervalued intrinsic discount
20 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Mpox And Smallpox Trial And Funding Setbacks Will Eventually Support A Stronger Outlook
Fair Value: US$6 88.6% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Diversified Vaccine And Cancer Therapy Platform Will Transform Long Term Earnings Potential
Fair Value: US$14 95.1% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
GeoVax Labs, Inc. Key Details
About GOVX
- Founded
- 1988
- Employees
- 19
- CEO
- WebsiteView website
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. It develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, the company offers GEO-MVA-MUC1, a vaccine candidate, which is in preclinical trial for the treatment of solid tumor cancers; GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-EMO1-Z, which is in preclinical trial for the treatment of Ebola Zaire; GEO-EMO1-S, which is in preclinical trial for the treatment of Ebola Sudan; GEO-MM01 treatment for marburg; and GEO-MVA for the treatment of Mpox and small pox. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; and the U.S. Department of Defense. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.
